dc.contributor.author
Atkinson, Sara Marie
dc.contributor.author
Bleil, Janine
dc.contributor.author
Maier, René
dc.contributor.author
Kühl, Anja A.
dc.contributor.author
Thorn, Mette
dc.contributor.author
Serikawa, Kyle
dc.contributor.author
Fox, Brian
dc.contributor.author
Kruse, Kim
dc.contributor.author
Haase, Claus
dc.contributor.author
Skov, Søren
dc.contributor.author
Nansen, Anneline
dc.contributor.author
Syrbe, Uta
dc.date.accessioned
2018-06-08T03:17:19Z
dc.date.available
2016-02-19T11:06:44.104Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/14857
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-19046
dc.description.abstract
Background The aims of the present study were to determine the relationship
between bone destruction and bone formation in the delayed-type
hypersensitivity arthritis (DTHA) model and to evaluate the effect of receptor
activator of nuclear factor κB ligand (RANKL) blockade on severity of
arthritis, bone destruction, and bone formation. Methods DTHA was induced in
C57BL/6 mice. Inflammation, erosive joint damage, and new bone formation were
semiquantitatively scored by histology. Osteoclast activity was assessed in
vivo, and messenger RNA (mRNA) expression of mediators of bone destruction and
bone formation were analyzed by mRNA deep sequencing. Serum concentrations of
tartrate-resistant acid phosphatase 5b, carboxy-terminal telopeptide I
(CTX-I), matrix metalloproteinase 3 (MMP3), and serum amyloid P component
(SAP) were determined by enzyme-linked immunosorbent assay. Anti-RANKL
monoclonal antibody treatment was initiated at the time of immunization.
Results Bone destruction (MMP3 serum levels, cathepsin B activity, and RANKL
mRNA) peaked at day 3 after arthritis induction, followed by a peak in
cartilage destruction and bone erosion on day 5 after arthritis induction.
Periarticular bone formation was observed from day 10. Induction of new bone
formation indicated by enhanced Runx2, collagen X, osteocalcin, MMP2, MMP9,
and MMP13 mRNA expression was observed only between days 8 and 11. Anti-RANKL
treatment resulted in a modest reduction in paw and ankle swelling and a
reduction of serum levels of SAP, MMP3, and CTX-I. Destruction of the
subchondral bone was significantly reduced, while no effect on bone formation
was seen. Conclusions Anti-RANKL treatment prevents joint destruction but does
not prevent new bone formation in the DTHA model. Thus, although occurring
sequentially during the course of DTHA, bone destruction and bone formation
are apparently not linked in this model.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Joint inflammation
dc.subject
Bone destruction
dc.subject
Bone formation
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Anti-RANKL treatment inhibits erosive joint destruction and lowers
inflammation but has no effect on bone formation in the delayed-type
hypersensitivity arthritis (DTHA) model
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Arthritis Research & Therapy. - 18 (2016), Artikel Nr. 28
dcterms.bibliographicCitation.doi
10.1186/s13075-016-0931-3
dcterms.bibliographicCitation.url
http://arthritis-research.biomedcentral.com/articles/10.1186/s13075-016-0931-3
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000023923
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000006008
dcterms.accessRights.openaire
open access